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ThOBJECTIVES The aim of this study was to evaluate dabigatran dual therapy versus warfarin triple therapy in patients
with or without diabetes mellitus in the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy With
Dabigatran Versus Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous
Coronary Intervention) trial.
BACKGROUND It is unclear whether dual therapy is as safe and efficacious as triple therapy in patients with atrial
fibrillation with diabetes following percutaneous coronary intervention.
METHODS In RE-DUAL PCI, 2,725 patients with atrial fibrillation (993 with diabetes) who had undergone PCI were
assigned to warfarin triple therapy (warfarin, clopidogrel or ticagrelor, and aspirin) or dabigatran dual therapy
(dabigatran 110 mg or 150 mg twice daily and clopidogrel or ticagrelor). Median follow-up was 13 months. The primary
outcome was the composite of major bleeding or clinically relevant nonmajor bleeding, and the main efficacy outcome
was the composite of death, thromboembolic events, or unplanned revascularization.
RESULTS Among patients with diabetes, the incidence of major bleeding or clinically relevant nonmajor bleeding was
15.2% in the dabigatran 110 mg dual therapy group versus 27.5% in the warfarin triple therapy group (hazard ratio [HR]:
0.48; 95% confidence interval [CI] 0.35 to 0.67) and 23.8% in the dabigatran 150 mg dual therapy group versus 25.1%
in the warfarin triple therapy group (HR: 0.87; 95% CI: 0.62 to 1.22). Risk for major bleeding or clinically relevant
nonmajor bleeding was also reduced with both dabigatran doses among patients without diabetes (dabigatran 110 mg
dual therapy: HR: 0.54; 95% CI: 0.42 to 0.70; dabigatran 150 mg dual therapy: HR: 0.63; 95% CI: 0.48 to 0.83). Risk for
the efficacy endpoint was comparable between treatment groups for both patients with and those without diabetes. No
interaction between treatment and diabetes subgroup could be observed, either for bleeding or for composite efficacy
endpoints.
CONCLUSIONS In this subgroup analysis, dabigatran dual therapy had a lower risk for bleeding and a comparable
rate of the efficacy endpoint compared with warfarin triple therapy in patients with atrial fibrillation with or without
diabetes following percutaneous coronary intervention. (J Am Coll Cardiol Intv 2019;12:2346–55) © 2019 The Authors.
Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N 1936-8798 https://doi.org/10.1016/j.jcin.2019.07.059
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AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial fibrillation
CI = confidence interval
CRNMBE = clinically relevant
nonmajor bleeding event
DTE = death or
thromboembolic event
HR = hazard ratio
MBE = major bleeding event
PCI = percutaneous coronary
intervention
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2347P atients with diabetes mellitus and coronary ar-tery disease have a higher risk for majoradverse cardiac events than patients without
diabetes (1–3). Patients with diabetes and atrial fibril-
lation (AF) also have a higher risk for ischemic stroke
(4,5), and it was found in the RE-LY (Randomized
Evaluation of Long-Term Anticoagulation Therapy)
trial that also dabigatran-treated patients with com-
bined AF and diabetes have a higher risk for both ma-
jor bleeding events and thromboembolic events
compared with those without diabetes (6). Further-
more, in patients with AF, coronary artery disease
was recently shown to be an independent risk factor
for thromboembolic events, including ischemic
stroke (7). Patients with diabetes and AF who undergo
percutaneous coronary intervention (PCI) may there-
fore have a particularly high risk of thromboembolic
events. In the RE-DUAL PCI (Randomized Evaluation
of Dual Antithrombotic Therapy With Dabigatran
Versus Triple Therapy With Warfarin in Patients
With Nonvalvular Atrial Fibrillation Undergoing
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ered for noninferiority for adverse bleeding
events as well as thrombotic-related events
using a composite of death, myocardial
infarction, stroke, systemic embolism, and
unplanned revascularization. While meeting
its primary endpoints concerning bleeding
and efficacy, it was further found, as part of
formal hierarchical testing, that dabigatran
110 mg dual-antithrombotic therapy was su-
perior to warfarin triple therapy with regard to
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unknown if dual therapy is adequate for PCI patients
with combined AF and diabetes. The aim of this pre-
defined subgroup analysis of the RE-DUAL PCI triala. Dr. Steg has received research grants from Bayer
lting fees from Amarin, Amgen, AstraZeneca, Bayer/
Novo Nordisk, Pfizer, Regeneron, Sanofi, and Servier.
te Cardiology, Medscape Cardiology, PhaseBio, and
A Research Institute, the Society of Cardiovascular
uality Oversight Committee; is a member of data
Harvard Clinical Research Institute, for the PORTICO
cluding for the ExCEED trial, funded by Edwards
t Sinai School of Medicine (for the ENVISAGE trial,
as received honoraria from the American College of
ce chair, ACC Accreditation Committee), the Baim
E-DUAL PCI clinical trial steering committee funded
Heart Letter), the Duke Clinical Research Institute
asive Cardiology), the Journal of the American College
inuing medical education steering committees), the
e, publications committee, steering committee, and
itor, Cardiology Today’s Intervention), the Society of
l education steering committees); is deputy editor of
ittee and the VA CART Research and Publications
aZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers
mix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron,
from Elsevier (editor, Cardiovascular Intervention: A
ik, Boston Scientific, St. Jude Medical (now Abbott),
cted unfunded research for FlowCo, Fractyl, Merck,
l fees from Bayer HealthCare, Boehringer Ingelheim,
and Zol. Dr. Nordaby is an employee of Boehringer
e, contracted by Boehringer Ingelheim International.
ed as a consultant for Bayer/Janssen, Bristol-Myers
aiichi-Sankyo; and has been a speaker for Bayer,
tronic (no fees are personally received). Dr. Oldgren
lheim, Bristol-Myers Squibb, Daiichi-Sankyo, Pfizer,
s from Accumetrics, AstraZeneca, Bayer HealthCare,
rer, The Medicines Company, and Pfizer; and has
received research grants from Amgen, Boehringer
has received consulting fees from Alnylam, Amarin,
erck, Pfizer, Regeneron, and Sanofi.
, accepted July 11, 2019.
Maeng et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 2 , N O . 2 3 , 2 0 1 9
Dabigatran Dual Therapy in Patients With Diabetes D E C E M B E R 9 , 2 0 1 9 : 2 3 4 6 – 5 5
2348was to assess if patients with diabetes and AF who
underwent PCI were adequately protected against
thromboembolic events by dual- versus triple-
antithrombotic therapy, while remaining protected
against bleeding events.
METHODS
The RE-DUAL PCI trial design, methods, and primary
results have been published (8,9). A brief summary of
design and methods is provided here.
PATIENT POPULATION. Key inclusion criteria were
men and women $18 years of age, with nonvalvular
AF, who underwent successful PCI with a bare-metal
or drug-eluting stent within the previous 120 h.
Nonvalvular AF could be paroxysmal, persistent, or
permanent, but it could not be secondary to a
reversible disorder unless long-term treatment with
an oral anticoagulant agent was anticipated. The
indication for PCI could be either an acute coronary
syndrome or stable coronary artery disease. Key
exclusion criteria were the presence of bioprosthetic
or mechanical heart valves, severe renal insufficiency
(creatinine clearance <30 ml/min), or other ma-
jor comorbidities.
TREATMENTS. Patients were randomly assigned to
receive 1 of 3 treatments: dual therapy with dabiga-
tran etexilate 110 mg twice daily plus either clopi-
dogrel or ticagrelor, dual therapy with dabigatran
etexilate 150 mg twice daily plus either clopidogrel or
ticagrelor, or triple therapy with warfarin plus either
clopidogrel or ticagrelor plus aspirin (#100 mg/day).
In the warfarin triple therapy group, aspirin was
discontinued after 1 month in patients in whom
bare-metal stents were implanted and after 3 months in
patients in whom drug-eluting stents were implanted.
Randomization was performed with the use of
permuted blocks, with stratification according to age
group (nonelderly or elderly [<80 or $80 years; <70
or $70 years in Japan]) and region (United States,
Japan, or other countries). All patients in the United
States and nonelderly patients in other countries
were randomly assigned to the dabigatran 110 mg
dual therapy group, the dabigatran 150 mg dual
therapy group, or the warfarin triple therapy group in
a 1:1:1 ratio. Elderly patients outside the United States
were randomly assigned to the dabigatran 110 mg
dual therapy or the warfarin triple therapy group in a
1:1 ratio; they were not eligible to be assigned to the
dabigatran 150 mg dual therapy group, in accordance
with the recommendations of the dabigatran label in
those countries. All the patients were to receive either
clopidogrel (75 mg/day) or ticagrelor (90 mg twicedaily) for at least 12 months after randomization; the
choice of agent was at the discretion of the investi-
gator. The dose of warfarin was adjusted to ensure
that the patient’s international normalized ratio was
within a range of 2.0 to 3.0.
ENDPOINTS. The endpoints in this subgroup analysis
reflect the primary endpoint in the primary publica-
tion, which was the time to first major bleeding event
(MBE) or clinically relevant nonmajor bleeding event
(CRNMBE) (as defined by the International Society on
Thrombosis and Haemostasis), and the main second-
ary endpoint, which was a composite efficacy
endpoint of time to death, first thromboembolic event
(myocardial infarction, stroke, or systemic embo-
lism), or unplanned revascularization (PCI or coro-
nary artery bypass grafting). Other endpoints were
the individual endpoints of International Society on
Thrombosis and Haemostasis MBE alone, CRNMBE
alone, intracranial hemorrhage, a combined endpoint
of death or thromboembolic event (DTE), as well as
death, myocardial infarction, definite stent throm-
bosis, and stroke. Detailed definitions of the
endpoints have been published (8). All clinical
endpoint events were adjudicated by an independent
committee whose members were unaware of the
treatment assignments.
STATISTICAL ANALYSIS. Clinical characteristics of
patients were summarized according to whether they
had diabetes. For comparison of the dabigatran
110 mg dual therapy group versus the warfarin triple
therapy group within the diabetes subgroup cate-
gories, stratified Cox proportional hazards regression
models, stratified by age (nonelderly vs. elderly
[age <70 vs. $70 years in Japan; <80 vs. $80 years
elsewhere]), were applied. Unstratified Cox propor-
tional hazard regression models were used for com-
parison of the dabigatran 150 mg dual therapy group
versus the warfarin triple therapy group. Exploratory
treatment-by-subgroup interaction p values resulting
from Cox proportional hazard regression models were
provided. A treatment-independent, stratified Cox
proportional hazard regression analysis was per-
formed including diabetes subgroup as the only factor
in the model. Furthermore, a multivariate stratified
Cox proportional hazard regression analysis including
diabetes subgroup as factor in the model and addi-
tionally adjusting for continuous variable age and
categorical variables sex and previous stroke
was performed.
RESULTS
The RE-DUAL PCI trial included 993 patients with
diabetes and 1,731 patients without diabetes; diabetes
FIGURE 1 Patients With and Without Diabetes in Each Treatment Group
*One month of aspirin for bare-metal stent; 3 months of aspirin for drug-eluting stent. †For the comparison with dabigatran 150 mg dual
therapy, elderly patients outside the United States were excluded. BID ¼ twice daily.
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2349status at inclusion was unknown for 1 patient, who
was excluded from this analysis (Figure 1). The me-
dian duration of follow-up was 13 months (inter-
quartile range: 9 to 18 months).
IMPACT OF DIABETES. The baseline characteristics
of patients with and without diabetes are presented
in Table 1. Rates of previous stroke, PCI, and coronary
artery bypass grafting were higher among patients
with diabetes.
Table 2 presents the clinical outcome events ac-
cording to the presence of diabetes. Patients with and
those without diabetes had a comparable bleeding
risk, but patients with diabetes had a higher risk for
the composite efficacy-related endpoints (DTE or
unplanned revascularization, as well as DTE alone)
(Table 2). The risk for the individual endpoints of
death (6.1% vs. 4.2%; hazard ratio [HR]: 1.50; 95%
confidence interval [CI]: 1.06 to 2.11) and stroke (2.4%
vs. 0.9%; HR: 2.86; 95% CI: 1.50 to 5.45) was also
higher for patients with diabetes, whereas risk formyocardial infarction was comparable (3.9% vs. 3.5%;
HR: 1.14; 95% CI: 0.76 to 1.70) and risk for definite
stent thrombosis was numerically lower (0.8% vs.
1.3%; HR: 0.63; 95% CI: 0.28 to 1.41) for patients with
versus those without diabetes. Similar results were
observed for the multivariable Cox proportional haz-
ard regression model.
DUAL VERSUS TRIPLE THERAPY IN PATIENTS WITH
AND WITHOUT DIABETES. The safety outcomes by
treatment group in patients with and those without
diabetes are presented in Figure 2, and the efficacy-
related endpoints are shown in Figure 3. No interac-
tion between treatment and diabetes subgroup could
be detected, either for the bleeding or for the efficacy
endpoints (Figures 2 and 3).
In patients with diabetes, the risk for bleeding
events was reduced by dabigatran 110 mg dual ther-
apy (Figure 2, Central Illustration). The bleeding
reduction by dabigatran 110 mg dual therapy was
numerically higher than that by dabigatran 150 mg
TABLE 1 Baseline Characteristics of Patients With Versus Those Without
Diabetes in the RE-DUAL PCI Trial
Patients With
Diabetes (n ¼ 993)
Patients Without
Diabetes (n ¼ 1,731)
Age, yrs 71  8 71  9
Male 720 (72.5) 1,349 (77.9)
BMI*, kg/m2 30.2  5.5 28.1  5.0
Diabetes treatment
Insulin only 122 (12.3) —
Insulin þ other 155 (15.6) —
Other only 716 (72.1) —
Previous stroke 95 (9.6) 131 (7.6)
CHA2DS2-VASc score 4.4  1.4 3.2  1.5
HAS-BLED score 2.8  0.7 2.7  0.7
Creatinine clearance†, ml/min 79.1  31.6 77.4  28.6
Previous MI 250 (25.2) 449 (25.9)
Previous PCI 376 (37.9) 536 (31.0)
Previous CABG 128 (12.9) 159 (9.2)
Type of AF
Persistent 165 (16.6) 319 (18.4)
Permanent 343 (34.5) 545 (31.5)
Paroxysmal 485 (48.8) 866 (50.0)
Baseline OAC treatment‡
Long term 355 (35.8) 573 (33.1)
Treatment naive 638 (64.2) 1,158 (66.9)
Indication for PCI§
Stable angina 453 (45.6) 729 (42.1)
Acute coronary syndrome 492 (49.5) 883 (51.0)
Staged procedure 170 (17.1) 292 (16.9)
Other 54 (5.4) 116 (6.7)
Type of stentk
Drug eluting 827 (83.3) 1,424 (82.3)
Bare metal 136 (13.7) 268 (15.5)
Drug eluting and bare metal 21 (2.1) 20 (1.2)
Other 5 (0.5) 16 (0.9)
Values are mean  SD or n (%). *Data missing from 1 and 3 patients with and without diabetes,
respectively. †Data missing from 88 and 143 patients with and without diabetes, respectively.
‡Fourteen days of consecutive OAC treatment used to classify into treatment-naive or long-term
OAC patients. §More than 1 indication per patient is possible. kData missing from 4 and 3 patients
with and without diabetes, respectively.
AF ¼ atrial fibrillation; BMI ¼ body mass index; CABG ¼ coronary artery bypass graft;
MI ¼ myocardial infarction; OAC ¼ oral anticoagulant agents (both non–vitamin K and vitamin K
antagonists); PCI ¼ percutaneous coronary intervention; RE-DUAL PCI ¼ Randomized Evaluation
of Dual Antithrombotic Therapy With Dabigatran Versus Triple Therapy With Warfarin in Patients
With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
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for the efficacy endpoint events for dabigatran 110 mg
dual therapy and dabigatran 150 mg dual therapy,
respectively, versus warfarin triple therapy did not
differ relevantly (Figure 3, Central Illustration).
In patients without diabetes, dabigatran 110 mg
dual therapy and dabigatran 150 mg dual therapy
were both found to reduce the risk for bleeding end-
points compared with warfarin triple therapy
(Figure 2). The risks for the composite efficacy
endpoint of DTE or unplanned revascularization werecomparable for the dabigatran 110 mg dual therapy
and dabigatran 150 mg dual therapy groups, respec-
tively, versus the warfarin triple therapy group
(Figure 3).
DISCUSSION
In the RE-DUAL PCI trial, dabigatran dual-
antithrombotic therapy reduced bleeding events,
without increasing the risk for major ischemic events,
compared with warfarin triple-antithrombotic ther-
apy (8). Herein, we present a subgroup analysis of the
RE-DUAL PCI trial in patients with and those without
diabetes. The aim was to assess if patients with AF
and diabetes undergoing PCI are adequately pro-
tected against thromboembolic events by dabigatran
110 mg dual therapy and dabigatran 150 mg dual
therapy versus warfarin triple-antithrombotic ther-
apy. Our main findings are as follows: 1) patients with
AF and diabetes have a higher risk for death and
thromboembolic events but do not have a higher risk
for bleeding compared with patients with AF alone; 2)
no interactions between the diabetes subgroup and
treatment could be observed, thus consistent results
with main RE-DUAL PCI trial were obtained; and 3)
dual therapy with dabigatran 110 mg had a lower risk
for bleeding and was as efficacious as triple therapy
with warfarin in patients with AF with and without
diabetes following PCI.
BLEEDING AND THROMBOEMBOLIC EVENTS IN
PATIENTS WITH AND THOSE WITHOUT DIABETES.
Presence of diabetes in this AF plus PCI cohort was
associated with a comparable risk for bleeding but a
higher risk for ischemic events in comparison with
patients without diabetes. The relevance of this
observation has hitherto not been examined in the
context of dual versus triple therapy. Risks for
bleeding and thromboembolic events share some
common risk factors. For example, the CHA2DS2-VASc
and HAS-BLED scores both include age, hypertension,
and previous stroke (10), and these 3 factors were
associated with both stroke and bleeding events in a
large Swedish study of patients with AF (4). More-
over, this coinciding increased risk was recently
found in the ASCEND (A Study of Cardiovascular
Events in Diabetes) trial, in which the incremental
risk for vascular events from low- to high-risk pa-
tients was closely matched by a similar incremental
risk for bleeding events (11). Similarly, when
comparing patients with AF with and without dia-
betes randomized in the RE-LY trial, both major
bleeding events (diabetes 4.2% vs. no diabetes
TABLE 2 Clinical Outcomes of Patients With Versus Those Without Diabetes in the RE-DUAL PCI Trial
Patients With
Diabetes
(n ¼ 993)
Patients Without
Diabetes
(n ¼ 1,731) HR* (95% CI) Adjusted HR† (95% CI)
Bleeding endpoints
ISTH MBEs or CRNMBEs 219 (22.1) 350 (20.2) 1.12 (0.95–1.33) 1.13 (0.95–1.33)
ISTH MBEs 68 (6.8) 114 (6.6) 1.07 (0.79–1.44) 1.07 (0.79–1.45)
CRNMBEs 168 (16.8) 267 (15.4) 1.11 (0.92–1.35) 1.11 (0.92–1.35)
Intracranial hemorrhage 4 (0.4) 10 (0.6) 0.71 (0.22–2.26) 0.70 (0.22–2.23)
Efficacy endpoints
Death, thromboembolic event, or
unplanned revascularization
156 (15.7) 214 (12.4) 1.29 (1.05–1.58) 1.28 (1.04–1.58)
Death 61 (6.1) 72 (4.2) 1.50 (1.06–2.11) 1.51 (1.07–2.12)
Death or thromboembolic event 114 (11.5) 137 (7.9) 1.47 (1.15–1.89) 1.47 (1.14–1.88)
Definite stent thrombosis 8 (0.8) 22 (1.3) 0.63 (0.28–1.41) 0.60 (0.27–1.36)
MI 39 (3.9) 60 (3.5) 1.14 (0.76–1.70) 1.11 (0.74–1.66)
Stroke 24 (2.4) 15 (0.9) 2.86 (1.50–5.45) 2.82 (1.48–5.39)
Values are n (%). *Cox proportional hazard model stratified by age (nonelderly vs. elderly [<70 or$70 yrs in Japan and <80 or$80 yrs elsewhere]). †Cox proportional hazard
model stratified by age (nonelderly vs. elderly [<70 or $70 yrs in Japan and <80 or $80 yrs elsewhere]) and adjusted for continuous variable age and categorical variables
gender and previous stroke.
CI ¼ confidence interval; CRNMBE ¼ clinically relevant nonmajor bleeding event; HR ¼ hazard ratio; ISTH ¼ International Society on Thrombosis and Haemostasis;
MBE ¼ major bleeding event; MI ¼ myocardial infarction; RE-DUAL PCI ¼ Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran Versus Triple Therapy With
Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
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23513.0% per year) and the composite of stroke or sys-
temic embolism (diabetes 1.9% vs. no diabetes 1.3%
per year) were higher in patients with diabetes (12). In
comparison, our data suggest that patients withFIGURE 2 Bleeding Events According to Treatment Group Among P
*From Cox proportional hazard model; stratified by age (elderly vs. non
dabigatran 150 mg dual therapy versus warfarin triple therapy. †For the
were excluded. CI ¼ confidence interval; CRNMBE ¼ clinically relevant n
Haemostasis; MBE ¼ major bleeding event; ND ¼ not done (at least 1 tdiabetes treated with oral anticoagulant therapy and 1
or 2 antiplatelet agents do not seem to have an
increased risk for bleeding compared with patients
without diabetes receiving similar medications.atients With and Those Without Diabetes
elderly) for dabigatran 110 mg dual therapy versus warfarin triple therapy; unstratified for
comparison with dabigatran 150 mg dual therapy, elderly patients outside the United States
onmajor bleeding event; HR ¼ hazard ratio; ISTH ¼ International Society on Thrombosis and
reatment group has no events, and HR cannot be calculated).
FIGURE 3 Efficacy-Related Events According to Treatment Group Among Patients With and Those Without Diabetes
*From Cox proportional hazard model; stratified by age (elderly vs. nonelderly) for dabigatran 110 mg dual therapy versus warfarin triple therapy; unstratified for
dabigatran 150 mg dual therapy versus warfarin triple therapy. †For the comparison with dabigatran 150 mg dual therapy, elderly patients outside the United States
were excluded. CI ¼ confidence interval; DTE ¼ death or thromboembolic event; HR ¼ hazard ratio.
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2352However, the expected magnitude of treatment effect
between patients with and without diabetes in this
setting is not known and this may challenge the
ability to detect differences.
DABIGATRAN DUAL THERAPY VERSUS WARFARIN
TRIPLE THERAPY IN PATIENTS WITH AND THOSE
WITHOUT DIABETES. There are relatively few studies
on the optimal treatment strategy in patients with AF
undergoing PCI, and none of these has looked atoutcomes in the diabetes subpopulation. There are
currently 5 randomized trials in mixed cohorts, with
RE-DUAL PCI being the second largest of those, all
showing that dual therapy decreases the risk for
bleeding events compared with triple therapy
(8,13–17). The latest of these showed elegantly that the
reduction of bleeding events with dual therapy with a
novel oral anticoagulant agent (apixaban) and clopi-
dogrel was due to both the omission of aspirin and the
superiority of the novel oral anticoagulant over
CENTRAL ILLUSTRATION Outcomes Summary of Dabigatran Dual Therapy Versus
Warfarin Triple Therapy Post-PCI in Patients With AF and Diabetes
Maeng, M. et al. J Am Coll Cardiol Intv. 2019;12(23):2346–55.
*This is subgroup analysis and thus not a priori powered for safety or efficacy. AF¼ atrial fibrillation; PCI¼ percutaneous coronary intervention.
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2354warfarin (17). In this RE-DUAL PCI substudy, the dia-
betes cohort consisted of 993 patients; this subgroup
alone was thus considerably larger than the approxi-
mately 600-patient mixed cohorts included in WOEST
(What Is the Optimal Antiplatelet and Anticoagulant
Therapy in Patients With Oral Anticoagulation and
Coronary Stenting) and ISAR-TRIPLE (Triple Therapy
in Patients on Oral Anticoagulation After Drug Eluting
Stent Implantation) (13,14). Moreover, this analysis
hitherto represents the only subgroup evaluation us-
ing data from a randomized clinical trial.
While confirming that dabigatran 110 mg dual
therapy reduces bleeding events and by showing
comparable outcomes for the main composite efficacy
endpoint, this diabetes subgroup analysis confirms
the main conclusions reported in the primary
RE-DUAL PCI publication. The results are also in
accordance with the RE-LY trial, in which the rate of
major bleeding was 3.4% per year in the warfarin
group, compared with 2.7% per year in the group
receiving 110 mg of dabigatran (p ¼ 0.003) and 3.1%
per year in the group receiving 150 mg of dabigatran
(p ¼ 0.31) (6). A RE-LY subgroup analysis suggested
that concomitant antiplatelet use increased major
bleeds by approximately 60% with a single anti-
platelet agent, and major bleeds were more than
doubled when dual-antiplatelet therapy was used
(18). The relative increase in bleeding risk in case of
antiplatelet use was similar between the 2 dabigatran
doses and warfarin, but the absolute rates of bleeding
were lowest in patients treated with dabigatran
110 mg (18). This information is important to tailor the
treatment to the individual patient. In 2 recently
updated consensus documents from both a European
and a North American perspective, it was recom-
mended that when dabigatran is used as part of dual
therapy, the 150-mg dose should be used in patients
considered to be at higher thrombotic risk, while the
110-mg dose can be considered in elderly patients and
those with high bleeding risk (10,19). Our data sup-
port this strategy for patients without diabetes.
Among those with diabetes, however, dabigatran
110 mg dual therapy seems to reduce bleeding events
to a greater extent than dabigatran 150 mg dual
therapy compared with warfarin triple therapy,
although the interaction p value was >0.05. Thus,
because of the limitations of this subgroup analysis
(see also the “Study Limitations” section), it is not
fully clear if the results from the dabigatran 150 mg
dual therapy versus warfarin comparison in the dia-
betic subgroup indicate a signal or are just a chance
finding. Furthermore, the point estimates of the HR
suggested comparable risk for the composite efficacyendpoint compared with warfarin triple therapy with
the caveat that the RE-DUAL PCI study was not
powered for subgroup analyses.
STUDY LIMITATIONS. First, this was a subgroup
analysis and consequently was powered neither for
statistical comparisons between treatment groups nor
for statistical interaction terms. Therefore, this sub-
group analysis is generally to be regarded as an
exploratory analysis, and observed results serve for
signal detection and hypothesis generation. Thus,
the absence of a statistically significant interaction
between treatment and the diabetes subgroup does
not necessarily imply consistency with the results
obtained in the overall population. In contrast, no
conclusions can be drawn purely on the results from
the single subgroup categories.
Second, because of multiple statistical testing, it is
possible that nominally statistically significant results
may be a play of chance.
Third, intracranial hemorrhage and stent throm-
bosis were both rare events, and this subgroup anal-
ysis, as well as the main study, was not powered for
individual endpoints. Nevertheless, we decided to
report these events because of their major influence
on clinical decision making.
Fourth, patients were randomized within 120 h
after successful PCI and received open-label treat-
ment, which according to guidelines included triple
therapy and therefore aspirin from PCI to randomi-
zation (10,19). Periprocedural aspirin treatment is
therefore still recommended.
Finally, our study included predominantly patients
of male sex, and the outcomes may differ between
men and women.
CONCLUSIONS
Dabigatran dual therapy had a lower risk for bleeding
than warfarin triple therapy in patients with AF with
or without diabetes following PCI. The point esti-
mates of the HR also suggest a similar risk for the
main composite efficacy endpoint, but one must keep
in mind that the RE-DUAL PCI study was not powered
for this efficacy endpoint in individual dose groups.
ACKNOWLEDGMENTS Editorial assistance limited to
formatting and figure preparation was provided by
Bill Wolvey from Parexel, with funding from Boeh-
ringer Ingelheim International.
ADDRESS FOR CORRESPONDENCE: Dr. Michael
Maeng, Department of Cardiology, Aarhus University
Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus
N, Denmark. E-mail: michael.maeng@ki.au.dk.
PERSPECTIVES
WHAT IS KNOWN? In the RE-DUAL PCI trial, dual
therapy with dabigatran 110 mg or 150 mg plus
clopidogrel or ticagrelor was superior for reducing risk for
bleeding events compared with triple therapy with
warfarin, aspirin, and clopidogrel or ticagrelor while being
noninferior regarding ischemic events. Diabetes mellitus
is a risk factor for adverse cardiovascular events in
patients with AF as well as following coronary stent
implantation.
WHAT IS NEW? Following coronary stent implantation
in patients with AF, patients with diabetes seem to have a
higher risk for DTE but not a higher risk for bleeding
compared with patients without diabetes. Consistent with
the main RE-DUAL PCI trial results, dual therapy with
dabigatran had a lower risk for bleeding and was as
efficacious as triple therapy with warfarin in patients with
AF with and without diabetes following PCI.
WHAT IS NEXT? These results with dabigatran dual
therapy following coronary stent implantation in patients
with diabetes should be confirmed by dual therapy with
other direct oral anticoagulant agents and with a study
sufficiently powered for the investigation of patients with
diabetes.
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